Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
GSH synthesis using the whole-cell biocatalyst was performed in 0.2 M phosphate buffer (pH 7.0) containing 40 mM l-glutamate, 20 mM l-cysteine, 40 mM glycine, 20 mM MgCl 2 and 20 mM ATP
(2025, August 27)
Start today
Duvyzats approval follows that of Sareptas Elevidys, which got the FDAs green light in June 2023, and Santhera Pharmaceuticals Agamree, which was approved in October
Mechanistically, there is a negative correlation between KLF2 and GPX4, and KLF2 deficiency increases the level of GPX4 and inhibits ferroptosis, promoting the invasion and migration of renal cancer cells, which can be reversed by overexpression of GPX4, 150 indicating that promoting ferroptosis of cancer cells may be a promising strategy for the clinical treatment of advanced RCC
US$ 29.27
US$ 20.15
US$ 28.45
US$ 25.26
